Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune, dives into the revolutionary world of TCR T-cell therapies. He shares insights on the TECELRA trial, which achieved FDA approval for Tecelra, a groundbreaking engineered T-cell therapy for solid tumors. The conversation highlights the intricacies of developing therapies for synovial sarcoma and the unique challenges in this field. Williams also compares TCR and CAR T-cell therapies, shedding light on their distinct advantages and the complexities of off-target effects in treatment.